Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price target on Wall Street implies significant upside potential. The drugmaker's ...
Finance), implies that the stock could skyrocket by about 462% from its current levels. Does that make it a buy? Terns Pharmaceuticals focuses on developing weight loss and oncology medicines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback